Aptorum Group Ltd

Aptorum is a clinical stage biopharmaceutical company focused on discovering, developing, and commercializing therapeutic assets for diseases with unmet medical needs, specifically in oncology (including orphan oncology indications) and infectious diseases. As of December 31, 2025 and the date of this filing, Aptorum operates in a single segment and no longer provides clinical services, focusing entirely on research and development. The company aims to develop novel and repurposed therapeutics and diagnostics technology across various disease areas. Its strategy involves expanding its portfolio with products that may achieve orphan drug designation or address unmet medical needs, collaborating with academic institutions and CROs, and growing its in-house pharmaceutical development center. Aptorum's lead projects are ALS-4 and SACT-1. ALS-4 is a small drug molecule designed to target bacterial virulence expression, which are products of bacterial genes that aid colonization, survival, or cause damage. This approach seeks to overcome antibiotic resistance. In March 2023, Aptorum completed Pre-IND discussions with the US FDA for ALS-4. SACT-1 is the first repurposed drug candidate from the proprietary Smart-ACT drug discovery platform. Its initial targeted indication is neuroblastoma, a rare cancer classified as an orphan disease, primarily affecting children aged 5 years and below, forming in nerve tissue, often in the adrenal glands, spine, chest, abdomen, or neck.